Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
KRAS G12C-mutant pancreatic ductal adenocarcinoma
Data

Cancers·KRAS G12C-mutant pancreatic ductal adenocarcinoma

DataKRAS G12C-mutant pancreatic ductal adenocarcinoma

Back to the KRAS G12C-mutant pancreatic ductal adenocarcinoma hub →56 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

56

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Pancreatic acinar cell carcinoma
Shares Eileen M. O'Reilly, Pancreatic cancer (KEGG map), KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Shares CA 19-9, Pancreatic cancer (KEGG map), Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Resectable pancreatic ductal adenocarcinoma
Shares Eileen M. O'Reilly, Revolution Medicines, CA 19-9, Daraxonrasib and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Pancreatic cancer (KEGG map), KRAS, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares KRAS, Comprehensive genomic profiling, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei
Shares KRAS and the tags subtype-page, gastrointestinal.

technologies

Comprehensive genomic profiling Cytotoxic chemotherapy KRAS & RAS inhibitors Liquid biopsy (ctDNA)Platinum agents Small-molecule kinase inhibitors Topoisomerase-I inhibitors (and ADC payloads)

targets

drugs

ApprovedSmall-molecule inhibitor (KRAS G12C)

Adagrasib · Krazati

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

Phase 3Small-molecule inhibitor (KRAS G12C)

Phase 2Small-molecule RAS(ON) G12C-selective inhibitor

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedSmall-molecule covalent KRAS G12C inhibitor

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedOral covalent KRAS G12C inhibitor

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

Phase 3Small-molecule inhibitor (KRAS G12C)

ApprovedSmall-molecule inhibitor (KRAS G12C)

Sotorasib · Lumakras

companies

Amgen Bristol Myers Squibb Eli Lilly (incl. Loxo)InventisBio Ipsen Jacobio Pharmaceuticals Revolution Medicines Roche / Genentech

pathways

Pancreatic cancer (KEGG map)RAS / RAF / MEK / ERK (MAPK)Receptor tyrosine kinase activation

terms

CA 19-9 Driver mutation Drug resistance (primary and acquired)KRAS mutation subtypes (G12C, G12D, G12V)Oncogene

trials

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer CodeBreaK 100 (pancreatic cancer cohort)Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 RASolute 302 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

roadmaps

KRAS roadmap: undruggable → G12C → pan-RAS

people

Andrew J. Aguirre Eileen M. O'Reilly Frank McCormick Kevan M. Shokat Tanios Bekaii-Saab

key papers

CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable

biomarkers

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-22 · Jude Gomila · Every pancreatic subtype page now rests on two to four la… · diff · file

Wikipedia

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of KRAS G12C-mutant pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/kras-g12c-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id kras-g12c-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.